App-Quantinova.ai

Systemic medication treatment patterns in Adults with Atopic Dermatitis (AD): Results From the European Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (EUROSTAD)

Marjolein de Bruin-Weller - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

N/A

Integrated Analysis of Abrocitinib for the Treatment of Adolescents with Moderate-to-Severe Atopic Dermatitis From the Phase 3 Clinical Trial Program

Amy Paller - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Pulmonary embolism

N/A

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Achievement of Absolute PASI Thresholds in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Mark Lebwohl - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

Apremilast

Deucravacitinib, a Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Psoriasis: Reductions in Individual Component Scores and Body Regions of the Psoriasis Area and Severity Index in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Jeffrey M. Sobell - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

Apremilast

Sex Differences in Treatment Patterns of Severe Hidradenitis Suppurativa Exacerbations

Nicole Mona Golbari - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Hidradenitis Suppurativa

N/A

Mutations in FLG, the gene-coding pro?laggrin/?laggrin, are associated with putative hay fever in patients with atopic dermatitis.

Satoko Minakawa - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Atopic Dermatitis

N/A

Ixekizumab treatment response: Consistency over time and at each visit in psoriatic arthritis

Joseph F. Merola - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Adalimumab

Efficacy and Safety of Abrocitinib According to Geographies

Andrew F. Alexis - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Sustained treatment effect of spesolimab over 12 weeks for generalized pustular psoriasis flares; results from the Effisayil 1 study

Boni Elewski - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Psoriasis 14, pustular

Interleukin

Bimekizumab treatment response is maintained up to 3 years in patients with psoriatic arthritis: responder analyses from BE ACTIVE, a phase 2b dose-ranging study, and its open-label extension

Joseph F. Merola - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

bimekizumab

Efficacy Responses Across Disease Severity and Treatment History Subgroups of Patients With Moderate to Severe Plaque Psoriasis Treated With Guselkumab: Pooled Results From VOYAGE 1&2 Through 5 Years

Kenneth B. Gordon - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

Adalimumab

Direct and Indirect Treatment Effect of Guselkumab on Anxiety and Depression in Patients With Psoriasis by Adjusting for Psoriasis Area and Severity Index (PASI) â€“ A Mediation Analysis

April Armstrong - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Depression

Adalimumab

Guselkumab Efficacy and Safety Through 5 Years Among Psoriasis Patients With and Without Metabolic Syndrome at Baseline: Results From VOYAGE 1 and VOYAGE 2

Joseph F. Merola - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Metabolic syndrome

Adalimumab

Correlation of Fatigue Severity and Psoriasis Severity, and the Treatment Effect of Guselkumab: A Detailed Analysis of SF-36 Vitality Scores From the VOYAGE 2 Study

Bruce Strober - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

Adalimumab

Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis (AD) Among Adults With Moderate-to-Severe AD Treated with Upadacitinib

Shawn G Kwatra - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Atopic Dermatitis

ABT-494

Impact of risankizumab on improving symptoms and health-related quality of life and reducing fatigue and pain among psoriatic arthritis patients with moderate-to-severe skin involvement: Evidence from two Phase III trials

Kim Papp - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Risankizumab

Fatigue in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from the CIMPACT phase 3 trial

Alice B. Gottlieb - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

Certolizumab pegol

Efficacy of Apremilast in Patients With Mild to Moderate Psoriasis Assessed by the Physician Global Assessment and Body Surface Area Composite Tool: Post Hoc Analysis From ADVANCE

Linda Stein Gold - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

Apremilast

Validation of the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) scale for assessing severity of GPP

A. David Burden - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Psoriasis 14, pustular

N/A

Real-world treatment patterns and outcomes up to 1 year among children aged <12 years with moderate-to-severe atopic dermatitis (AD) enrolled in the PEDIatric STudy in Atopic Dermatitis (PEDISTAD) observational study

Eulalia Baselga - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

Cyclosporine eent

Filters

45280 Abstracts